Zum Team

James McLaren

Managing Director

James is a managing director at TM Capital, one of Oaklins’ US member firms, and co-heads the firm's healthcare team. He also co-leads Oaklins’ medical devices team and has an extensive background in the healthcare industry. Recent transactions include two equity financings for Analytics Life, aggregating in excess of US$40 million, and multiple merger advisory transactions, including the sale of Ultimed, a producer of pen needles and syringes for insulin-dependent patients, to a US private equity firm; the sale of VIP Petcare, a provider of veterinary services, to PetIQ, a NASDAQ-listed veterinary products company; and the sale of Sapheon, a manufacturer of products to treat venous insufficiency, to Covidien, a US public company subsequently purchased by Medtronic (NYSE – MDT).

James joined the firm from Asante Partners, which he founded more than 20 years ago to provide quality strategic advice to middle-market healthcare companies. Previously, he had a 20-year career advising corporate clients at Goldman Sachs, where he served as head of European corporate finance in London and of international corporate finance in New York, leading teams that executed significant global transactions. James has a BA in Economics (honors) from Oxford University. He is an advisory board member of Radius Ventures, a New York-based venture capital firm focused on the healthcare industry.

 James McLaren
Standort
New York, Vereinigte Staaten

E-Mail
jmclaren@tmcapital.com

Telefon
+1 212-809-1414

Mobile
+1 212-809-1414

Private Equity | Gesundheitswesen

TDK Corporation has divested its medical business HTI Medical to GTCR-backed Resonetics

Mehr erfahren
Gesundheitswesen

LDI has sold UltiMed to Levine Leichtman Capital Partners

Mehr erfahren
Private Equity | Gesundheitswesen

Metrigraphics has been acquired by Cirtec Medical Corp.

Mehr erfahren